CRYOPORT, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
CRYOPORT, INC. (CYRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.20% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-08-06
- CRYOPORT, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2026-03-31 was 3.80%, a 5.00% decline year-over-year.
- CRYOPORT, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-03-31 was 4.00%, a 9.09% decline year-over-year.
- CRYOPORT, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2024-03-31 was 4.40%, a 22.22% increase year-over-year.
- CRYOPORT, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2023-03-31 was 3.60%, a 56.52% increase year-over-year.
- CRYOPORT, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.00%, a 11.11% decline from fiscal 2024.
- CRYOPORT, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.50%, a 2.27% increase from fiscal 2023.
- CRYOPORT, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.40%, a 18.92% increase from fiscal 2022.
- CRYOPORT, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 3.70%, a 213.56% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2026-06-30 | 4.20% 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | 3.80% 10-Q · filed 2026-05-05 | |||
| 2025-12-31 | 4.00% 10-K · filed 2026-03-05 | |||
| 2025-09-30 | 4.00% 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | 4.00% 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | 4.00% 10-Q · filed 2026-05-05 | |||
| 2024-12-31 | 4.50% 10-K · filed 2026-03-05 | |||
| 2024-09-30 | 4.50% 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | 4.50% 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | 4.40% 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | 4.40% 10-K · filed 2026-03-05 | |||
| 2023-09-30 | 4.40% 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | 4.10% 10-Q · filed 2023-08-09 | |||
| 2023-03-31 | 3.60% 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | 3.70% 10-K · filed 2025-03-07 | |||
| 2022-09-30 | 3.70% 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | 3.60% 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | 2.30% 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | 1.18% 10-K · filed 2024-03-13 | |||
| 2021-09-30 | 0.90% 10-Q · filed 2022-11-04 | |||
| 2021-06-30 | 0.90% 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | 0.90% 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | 1.70% 10-K · filed 2023-02-28 | |||
| 2020-09-30 | 1.70% 10-Q · filed 2020-11-06 | |||
| 2020-06-30 | 1.70% 10-Q · filed 2020-08-10 | |||
| 2020-03-31 | 1.70% 10-Q · filed 2020-05-08 | |||
| 2019-12-31 | 2.57% 10-K · filed 2022-02-28 | |||
| 2019-09-30 | 2.60% 10-Q · filed 2019-11-12 | |||
| 2019-06-30 | 2.60% 10-Q · filed 2019-08-09 | |||
| 2019-03-31 | 2.60% 10-Q · filed 2019-05-09 | |||
| 2018-12-31 | 3.07% 10-K · filed 2020-03-10 | |||
| 2017-12-31 | 2.23% 10-K · filed 2019-03-13 | |||
| 2015-03-31 | 2.03% 10-K · filed 2015-05-19 | |||
| 2014-06-30 | 1.64% 10-Q · filed 2014-07-31 | |||
| 2014-03-31 | 1.84% 10-K · filed 2015-05-19 | |||
| 2013-12-31 | 1.84% 10-Q · filed 2014-02-13 | |||
| 2013-09-30 | 1.84% 10-Q · filed 2013-11-18 | |||
| 2013-06-30 | 1.69% 10-Q · filed 2013-08-14 | |||
| 2013-03-31 | 2.22% 10-K · filed 2013-06-25 | |||
| 2012-12-31 | 2.22% 10-Q · filed 2014-02-13 | |||
| 2012-09-30 | 2.22% 10-Q · filed 2013-11-18 | |||
| 2012-06-30 | 2.22% 10-Q · filed 2013-08-14 | |||
| 2012-03-31 | 2.87% 10-K · filed 2013-06-25 | |||
| 2011-06-30 | 2.87% 10-Q · filed 2012-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |